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“In order to get a big answer you need to ask a big question” 
Peter Medawar, 1960 
and this is just a small crack to let a little light in 
Marita Lagergren Lindberg 























    To my family 
 








Acute myeloid leukemia (AML) is a severe, life threatening malignancy characterized 
by a clonal expansion of immature myeloid cells in the bone marrow, resulting in severe 
infections and bleedings. High dose chemotherapy is able to normalize the blood and bone 
marrow morphology (complete remission, CR) in a majority of treated patients, but 
recurrent disease, typically occurs within 1-2 years. Since further intensification of 
chemotherapeutic regimens is usually ineffective and accompanied by excess toxicity, 
novel approaches using better-targeted drugs are now being assessed. We have analysed the 
effects of one such new agent, gemtuzumab ozogamicin (GO) on AML cells and have also 
looked for biomarkers of clinical response and the role of multidrug resistance (MDR) 
expression utilizing biobanked cells from an AML cohort with known long-term 
therapuetic outcome. In paper I we analysed apoptotic signalling in response to GO, a 
monoclonal CD33 antibody conjugated to the DNA-double strand break-inducing toxin 
calicheamicin. The CD33 antigen is typically expressed on AML blast cells, but not on e.g. 
normal gut cells. We found that GO could induce mitochondrial depolarisation, activation 
of caspase-3 and decreased viability of primary cells from AML patients and AML cell 
lines. Moreover, we showed that GO activated the proapoptotic proteins Bak and Bax, 
regulators of mitochondria-mediated apoptotic signalling. Importantly, none of the above 
events could be observed in GO-resistant AML cells. In paper II, we looked at the role of 
caspase-2 in GO- or  daunorubicin-induced apoptotic signalling. We noted that both drugs 
caused cleavage of caspase-2 into its active form. A selective caspase-2 inhibitor prevented 
GO-induced caspase-3 activation, yet did not influence the activation of Bak and Bax. All 
in all, our data indicate that both mitochondria-dependent and independent routes to 
caspase-3 activation are involved in GO-induced apoptotic signalling, findings that may 
lead to novel future therapeutic approaches for AML. Improved predictive biomarkers for 
treatment response are clearly needed to enable more personalized and effective therapeutic 
options in AML. In paper III we studied peripheral blood cells from 42 patients diagnosed 
with AML and subjected to induction chemotherapy, aiming to identify biomarkers of CR 
duration using global gene expression analysis (Affymetrix®). Prominent differences in 
gene expression were found with a remarkable up-regulation of the transcription factor 
RUNX1T1 in patients with short vs. those with long subsequent CR duration. Network 
analyses (Oncomine®) revealed multiple transcription factors as interactors to RUNX1T1, 
out of which TCF3 was also significantly up-regulated in patients with short CR duration. 
An in silico validation, taking advantage of previously published data from two other 
independent AML cohorts revealed 52 genes to be regulated in all three cohorts. Among 
these genes CXCL3, ZMIZ1 and PRDX2 attracted a special interest due to their reported 
involvement in cancer, leukemia, apoptosis and proliferation. Thus, CXCL3 and ZMIZ1, 
with known involvement in tumorgenesis, had increased expression in poor responders 
whereas PRDX2, a tumour suppressor gene, instead showed a decreased expression. In 
paper IV we investigated the clinical relevance of 380 genes, reported to have a role in 
multidrug resistance (MDR) and analyzed 11 paired sampled from AML patients, collected 
at diagnosis and at time of relapse. Unsupervised hierarchical clustering showed that half of 
the cases had a similar expression pattern at both time points, whereas in the remaining 
patients the MDR genes became altered, suggesting clonal evolution. Patient-by-patient 
analyses showed signs of unique individual patient gene signatures and in 10 out of 11 
patients an increase of at least one ABC transporter was observed at relapse. These 
findings call for a more broad signalling analysis of diagnostic and relapse AML blasts in 
order to improve chemotherapy response and thereby overall survival of the individual 
AML patient. 
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1. ACUTE MYELOID LEUKEMIA 
Acute myeloid leukemia (AML) is a malignant disease characterized by an 
accumulation of immature myeloid blast cells in the bone marrow and most often in the 
peripheral blood. AML can also be present in other tissues such as in the skin, 
(leukemia cutis) [1] [2]. The clonal expansion of myeloid precursor cells in AML 
interfere with normal myelopoiesis and results in deficient function of normal blood 
cells which in turn leads to AML associated symptoms i.e. fatigue, bleedings and 
severe infections, some which are lethal. Immunophenotypic analysis by flow 
cytometry is a useful tool in AML in order to e.g. detect “myeloid” or “lymphoid” cell 
markers, making it possible to distinguish between minimally differentiated AML and 
acute lymphoblastic leukemia (ALL) [3] [4]. In mixed phenotype acute leukemia the 
blast populations express antigens characteristic of both myeloid and lymphoid 
lineages, which again makes flow cytometry analysis valuable [3]. Minimal residual 
disease (MRD) is defined as remaining leukemic cells in patients in whom 
morphological complete remission of the bone marrow has been achieved (described 
further in 1.1.2). Flow cytometry can also be used to detect MRD, since the technique 
can identify aberrant, malignant antigen combinations making it possible to distinguish 
leukemic cells from normal hematopoietic cells, with high sensitivity [5] [6]. AML is a 
severe life threatening disease. It occurs in all ages but is more common in the elderly 
[7] [8] with a median age at diagnosis of approximately 70 years [8]. Approximately 
320 adults are diagnosed with AML in Sweden every year [9] making it the most 
common acute leukemia diagnosis in adults [10]. This corresponds to an annual 
incidence of 3-4/100 000 individuals, an incidence which is similar to that in other 
western countries [11] [9] [10].  
1.1  BACKGROUND 
In 1845 Rudolf Virchow (1821-1902) described patients at autopsy, with specific 
findings including splenomegaly and altered colour and consistency of the blood [12] 
[13].  Virchow proposed the term “leukemia”, a greek word meaning “white blood” 
[12]. In 1891 new methods for staining blood cells were introduced, confirming that the 
myeloid leukemia cells were predominantly of granulocytic morphology [13].  
 Although “acute leukemia” has been a recognized disease since many years, it was 
not until the 1970s that a group of French, American and British leukemia experts 
(FAB) divided this entity into several subtypes. This classification was mainly based on 
the morphology, including the maturation stage of the dominating cell types of each 
subgroup. This FAB classification was introduced in 1976 [14] and modified in 1985 
[15](Table 1A). Some leukemia subtypes in the classification system are linked to 
rather distinct symptoms, e.g. in patients with the M3 subtype (acute promyelocytic 
leukemia, APL), bleeding disturbances such as disseminated intravascular coagulation 
(DIC) are more frequently seen. The leukemic cells of patients with M0 to M5 are 
morphologically identified as precursors of white blood cells. FAB M6 and M7 are 
linked to immature forms of red blood cells and platelets, respectively. In order to 
incorporate the growing amount of knowledge, the World Health Organization (WHO) 
has introduced a novel classification system that takes into account the interrelation 
between morphology, cytogenetics, molecular genetics and immunologic markers, [3] 
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[16] (Table 1B). The aim is to make this system universally applicable and 
prognostically valid.  
 
Table 1 Acute myeloid leukemia classification systems. (A) The French-American-
British classification, dividing AML subtypes according to morphological 
characteristics of the leukemic cells. (B) The World Health Organization classification, 









1.1.1  Etiology 
The etiology of AML is generally unknown. It appears clear that previous treatment 
with chemotherapeutic agents [17], as well as preceding haematological malignancies, 
such as myeloproliferative disease and myelodysplastic syndromes, increase the risk of 
later developing AML. In some patients an association with exposure to ionizing 
radiation or benzene has been observed [18] [19]. Already in 1948 observant clinicians 
noticed a high incidence of leukemia in the population exposed to the atomic-bombs, 
which fell over Hiroshima and Nagasaki in August 1945, described by Folley and 
colleges [20]. This observation became an important starting point for the large 
epidemiological project, the Life Span Study (LSS), which has followed a sizable 
cohort of Japanese atomic-bomb survivors during several decades [18]. An increase in 
leukaemias occurred very soon after the blast (i.e. within the first 5 years), but the risk 
also subsided quickly and was dependent on the age of the exposed individual (i.e. a 
higher risk when exposed at a younger age) [18]. Benzene is regarded as a prototype for 
environmental leukemogenesis, where chronic exposure is associated with an increased 
risk of AML. It has been assumed, that AML derived from benzene exposure is similar 
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although recent data have suggested a closer resemblance to de novo AML [19]. It is 
evident that previous treatment with chemotherapeutic agents [17], as well as preceding 
haematological malignancies such as myeloproliferative disease and myelodysplastic 
syndromes, increase the risk of later developing AML.   
1.1.2  Treatment 
In AML multimodal chemotherapy is used in order to re-establish normalization of 
the blood and bone marrow cell numbers and morphology, leading to normalization of 
the clinical status of the patient, a state defined as complete remission (CR) [22] [23] 
(Table 2). 
 
Table 2: Complete remission criteria for response of treatment in AML patients 
according to the European LeukemiaNet [22] [23].  
 
Complete remission 
Bone marrow blasts < 5%; 
without the requirement of cell concentration in the marrow (counted ≥ 200 nucleated 
cells), 
with the absence of blasts with Auer rods, 
with presence of regenerating poeses 
Abscece of extramedullary leukemia 
Absolute neutrophil count  > 1.0 x 109/L 
Platelet count  > 100 x 109/L 
Independence of red cell transfusion1 
No minimum duration of response required 
1This requirement is included in the international ELN guidelines, but has not been applied in the 
corresponding Swedish guidelines [24] , mainly because of varying policies for erythrocyte transfusions.   
 
 
Current standard induction chemotherapy treatment typically consists of an 
anthracyclin in combination with high-dose cytarabine [25] [26]. The first anthracyclin 
to be introduced was daunorubicin [27], which still, together with cytarabine, 
constitutes the cornerstone in modern AML treatment. Although a number of other 
antileukemic drug combinations have been introduced as induction treatment, none of 
them have been convincingly shown to be superior to daunorubicin/cytarabine (DA) 
[26] [17] [25]. In recent publications, a dose intensification of daunorubicin was 
suggested to be tolerable and resulting in superior survival [28]. A “full dose” induction 
treatment generally induces CR in approximately 70-80% of treated patients [29] [22]. 
In Sweden, almost all patients under the age of 70, half of the patients between 70 and 
80 years and sporadic patients above 80 years of age, will receive intensive 
chemotherapy with curative intent [30] [31]. After achieving CR, a consolidation 
treatment, often with high doses of cytarabine (two to four courses), is generally given 
to prevent relapse of the disease [32] [33] [34]. One potential curative option for AML 
patients is allogeneic hematopoietic stem cell transplantation (SCT), usually performed 
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during first or subsequent CR. Despite intensive postremission therapy, and/or SCT, 
only a subgroup of patients with AML will be truly cured [35]. Even in the absence of 
morphologically detectable disease, at the time of transplantation, relapse post-SCT is a 
major cause of treatment failure [36]. Walter and colleagues have suggested that the 
minimal residual disease (MRD) status (i.e. the level of remaining disease after 
preceding chemotherapy), rather than the number of CRs, to be the most important 
factor to predict the risk of post-SCT relapse and long-term outcome [6] [37]. Most 
patients in CR will develop recurrent disease, often within 1-2 years. The long-term 
outcome in AML is therefore still poor, with a potential for long-term cure for 
approximately 40-45% of younger AML patients [38], and as low as <10% for patient 
cohorts above 60 years [39] [7] [28].  
1.2  PROGNOSTIC FACTORS 
Prognostic risk factors for AML (i.e. the risk of recurrent disease, usually linked to 
survival [39]) can be divided into 1) patient related factors 2) leukemia related factors 
and 3) response related factors which are further describes below.  
1.2.1  Patient related factors 
The most well established independent factor for poor prognosis is age [7] [40] [41] 
(Figure 1). The poorer outcome in elderly patients can be due to the fact that drug 
resistance and unfavourable cytogenetics are more commonly observed in this patient 
cohort [42] [43]. In addition, at older age the patients more often suffer from a poor 
performance status [44] or severe comorbidities, by themselves independent patient 
related risk factors [45] [46]. Despite this there are reports suggesting that some elderly 
will benefit from intensive chemotherapy [47]. Hypomethylating agents, such as 
azacitidine and decitabine, can sometimes induce long-term disease control without 
necessarily achieving CR and are some time used as an alternative to intensive 
chemotherapy [48] [49] [50] [51]. In addition, poor performance status, comorbidity 
and high white blood cells are shown to be risk factors for early death (i.e. induction 
related death) [7] [40] [41].  
1.2.2  Leukemia related factors 
Leukemia related factors include cytogenetic aberrations, associated hematopoietic 
disease, therapy-related disease and a high amount of white blood cells at diagnosis 
[42] [52]. As described above, the cytogenetics (chromosomal banding analysis) is 
considered very important for classification and clearly provides a powerful method to 
differentiate biologically and prognostically subgroups of AML [3] [53]. Cytogenetic 
aberrations are detected in approximately half of all adults diagnosed with AML [54] 
[55] and there are specific aberrations that are strong determinants of prognostic 
outcome and therapeutic response. The aberrant karyotypes distinguish three clinically 
important prognostic patient categories: those with favourable, intermediate and 
unfavourable cytogenetic, respectively. Thus, these analyses are important for 
stratification and to guide treatment approach [3] [53]. In addition, the number of 
specific information that can predict treatment outcome include not only cytogenetics, 
but also an increasing list of molecular features such as somatically acquired mutations 
of genes, i.e. FMS-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1), Mixed-
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lineage leukemia (MLL), Wilms tumor 1 (WT1), CCAT/enhancer binding protein 
alpha (CEBPalpha) and MDS1 and EVI1 complex locus (EVI1) [56-58] [38, 59].  
1.2.3  Response related factors 
After start of treatment, there are several important signs that have been linked to long-
term clinical outcome. One of these is the early assessment of bone marrow blast 
content after administration of induction chemotherapy, where the threshold value is set 
to 10% blast cells at day 15 from the therapy initiation [60] [61]. This value is 
prognostically relevant, since the degree of blasts that is cleared from the bone marrow 
may reflect chemotherapy resistance [62]. A well known parameter that reflects the risk 
of relapse and overall survival is the response to induction treatment, i.e. whether the 
patient requires one or several induction regimens to reach CR [63]. In addition, high 
MRD levels are associated with an increased relapse rate and inferior overall survival 
[64] [65] [66]. Measuring the presence of MRD throughout therapy, usually through 
flow cytometry, provides a possibility to make a more tailored treatment approaches 
[53].  
As can be seen in the classification systems AML is not a homogeneous disease, but 
rather a group of diseases (Table 1). Decades of research have demonstrated that 
patients with AML differ widely both clinically (i.e. in response to standard treatment) 
and in molecular, genetic and epigenetic characteristics [50] [67]. The enormous 
heterogeneity in the latter appears to indicate that optimal management of AML will 
eventually involve many specific regimens, with APL being an obvious example. The 
identification of APL is important, since this AML subtype responds very well to drug 
regimens containing all-trans retinoid acid (a vitamin A analogue) and since bleeding 
complications are more common, but manageable. The prognosis for APL has changed 
from the worst of the AML subtypes to, currently the best [68]. 
1.3  PREDICTION – NEW STRATEGIES 
To predict therapeutic response is becoming increasingly valuable in clinical 
management of AML patients. As described in solid tumours treated with targeted 
therapy, such as cetuximab in colorectal cancer [69], trastuzumab in metastatic breast 
cancer [70] and imatinib in gastrointestinal stromal tumours [71], reliable biomarkers to 
predict treatment response are necessary to select the optimal treatment for each patient. 
The heterogeneity in AML is reflected by a number of biological and clinical features 
that are used to predict the likelihood of response to a certain therapy. By dividing 
patients into different subgroups, a better survival prediction is allowed, but this has 
still limited impact on treatment strategies with a few exceptions (e.g. all-trans retinoic 
acid in APL) [72]. 
1.4  MULTIDRUG RESISTANCE 
Despite intensive treatment in AML, usually consisting of DA (see 1.1.2), the long-
term outcome is poor. Although advances in knowledge and understanding of the 
pathophysiology of AML have increased during the last decades, there have been only 
minor improvements regarding therapy. Resistance to chemotherapy is still a major 
obstacle. Cells selected for resistance to a single drug, might also show cross-resistance 
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to other structurally and mechanistically unrelated drugs, a phenomenon known as 
multidrug resistance (MDR) [73] [74]. MDR is mediated by families of genes encoding 
efflux transporters (both ATP and non-ATP dependent transporters), drug uptake 
transporters, DNA repair proteins and phase I and II drug-metabolizing enzymes and 
inhibition of different cell death pathways e.g. apoptosis [73] [74].  
The ATP-binding cassette (ABC) transporters are important mediators of multidrug 
resistance in patients with cancer [75] [73]. This family now consists of 49 different 
types, subdivided into seven different categories (ABCA though ABCG), and are 
expressed in both normal and malignant cells [76]. Three of those groups contains ABC 
transporters involved in multidrug resistance [76]. A number of these ABC transporters 
are known to transport drugs commonly used in the treatment of AML, such as 
anthracyclines and vinca alkaloids [73]. ABCB1 (ATP-binding cassette, subfamily B, 
member 1; also known as MDR1/P-glycoprotein) is expressed in lymphocytes and to a 
high extent in hematopoietic stem cells [77]. Moreover, ABCB1 is highly expressed in 
leukemic blasts [78] and is the most extensively studied transporter found to be higher 
expressed in secondary leukemias and reported to be associated with poor prognosis 
[78] [74].  
1.5  TARGETED THERAPY IN AML  
AML remains a very aggressive cancer disease with severe prognosis. Increased 
survival among younger AML patients, with further intensification of chemotherapy, is 
limited by toxicity and compromised by reduced compliance [79] [80]. One possible 
strategy to circumvent the toxic side effects is to use a treatment, which is directed 
specifically against the leukemia cells in combination with standard chemotherapy. 
Much effort has been invested during the last few decades in identifying molecular and 
genetic aberrations in AML. Although leukemogenic mutations such as those in 
CEBPA, FLT3, and NPM1, have been identified [56] [59] [38], recurrent genetic 
lesions appears to be insufficient in explaining the biological diversity of clinical AML. 
Epigenetic changes in chromatin structure, such as histone acetylation and methylation 
status are now intensively studied and are becoming important for the development of 
personalized therapy [81] [82] [83]. During the last few years there has been 
considerable research on targeted drugs, including small molecules and antibodies. For 
the treatment of AML, one promising antibody is gemtuzumab ozogamicin (GO; 
Mylotarg®), which was studied in the current thesis.  
1.5.1  Gemtuzumab ozogamicin 
Gemtuzumab ozogamicin (GO; Mylotarg®) is a targeted therapy that consists of a 
humanized monoclonal antibody (immunoglobulin G4, (hP67.6)) directed against 
CD33, a cell surface antigen. The active component of GO, calicheamicin	  (N-acetyl γ1 
calicheamicin), is a highly potent antitumor antibiotic and a DNA-targeting toxin [84] 
[85] [86]. When GO binds to the CD33 antigen the complex internalizes into the cell 
lysosomal compartment. The linker between the antibody and the toxin is stable at 
physiologic pH but allows hydrolytic release of the calicheamicin moiety at low pH 
such as in the lysosomes [85]. The toxin is reduced to 1,4-dehyrobenzene enters the cell 
nucleus and intercalates within the minor grove of the DNA helix causes site-specific 
DNA double strand breaks (DNA dsbs) (Figure 1). The target antigen of GO, CD33, is 
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expressed on immature normal cells of myelomonocytic lineage in healthy bone 
marrow but is not expressed on hematopoietic stem cells or on endothelial cells in the 
gastrointestinal tract. More important for AML patient response, CD33 is expressed by 
the leukaemia blast cells in approximately 90% of all AML patients [87] [86]. The fact 
that CD33 is not expressed on mature hematopoietic cells or endothelial cells appears 





Figure 1: Gemtuzumab ozogamicin cellular signalling 
 
GO was formally registered in the US for treatment of a subset of elderly AML-
patients, i.e. patients who due to physical status were not considered fit to receive 
conventional high dose chemotherapeutics [89] [90] [91]. Post approval, additional 
clinical trials were prompted and the Southwest Oncology Group (SWOG) initiated 
S0106, a randomized trial, comparing GO in combination with standard induction 
therapy with daunorubicin (D) and cytarabine (A), versus DA alone. As a second 
randomization, the trial also tested whether GO given as a post-consolidation therapy 
could improve disease-free survival. The trial accrual was stopped early (in August 
2009) when a higher early treatment-related mortality and no clinical benefit could be 
observed in the experimental group receiving GO, as compared to the comparator 
group receiving standard chemotherapy alone [91]. This led to a voluntary withdrawal 
of the drug from the US market. In Europe, GO has been used under license and in 
controlled clinical trials, with promising results [87]. Used as a single drug, GO has 
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shown clear anti-leukemic activity with clinically relevant responses in approximately 
30% of AML-patients treated in relapse [90].  
Recently, leading haematologists have made a case for reapproval of GO in AML 
based on results from four completed randomized studies supporting the efficacy of this 
agent in newly diagnosed AML with acceptable toxicity [92]. In acute promyelocytic 
leukemia (APL), GO is shown to be effective both as a single drug and in combination 
with all-trans retinoic acid (ATRA), likely because of high surface expression of CD33 
in APL cases [93] [94]. A number of studies have indicated that GO improves survival 
also in subsets of non-APL patients, supporting that CD33 is a clinically relevant target 
in some AML patient subsets [95] [96] [97] [86].  
1.5.2  Apoptotic signalling cascades 
Apoptosis is a type of cell suicide program, which is found in all our cells [98]. 
Apoptosis is essential for clearance of the cells that are, in some way damaged, infected 
or at the end of their normal life span. In the body this type of death doesn’t trigger an 
inflammatory response, as would be the case if necrotic cell death took place. The 
morphological hallmarks of apoptosis include DNA fragmentation, chromatin 
condensation, cell shrinkage and membrane blebbing [99] [100] [98]. Important for 
causing the hallmarks of apoptosis are caspases, a family of cysteine proteases [101]. 
Caspases can roughly be divided into either initiator (caspase-2, -8, -9 and -10) or 
executor (caspase-3, -6 and -7) caspases, the former being capable of autoproteolytical 
activation and trigger proteolytically cleavage of the latter, which carries out the 
selective substrate proteolysis giving rise to the apoptotic morphology features [102] 
[101]. In principal the apoptotic cell death signalling cascades can be triggered via an 
extrinsic or an intrinsic pathway [101], i.e. via death receptor or mitochondria-mediated 
route resulting in caspase activation. The death receptor pathway is exemplified by the 
binding of FAS ligand to the FAS receptor, leading to recruitment, dimerization and 
activation of caspase-8. Active caspase-8 will then activate the executioner caspases 
(caspase-3, -6 and -7) or activate the intrinsic pathway. The intrinsic pathway, also 
referred to as the mitochondrial pathway, is activated through different cellular stresses, 
e.g. growth factor deprivation, DNA damage among others [101], subsequently leading 
to activation of a subclass of Bcl-2-family of proteins, BH3-only proteins. Moreover, 
the BH3-only proteins play a critical role as they function to integrate signals from both 
DNA-damage as well as from growth factor receptors onto the Bcl-2 family proteins 
Bak and Bax, which are in part responsible for mitochondrial release of cytochrome c 
[103]. Bak, which is situated in the outer mitochondrial membrane, undergoes several 
N-terminal conformational changes [104] so that its multimerization and interaction 
with Bax is possible [105]. Bax, situated in the cytoplasm, respond to DNA damage by 
a conformational change that allows integration in the outer mitochondrial membrane 
and formation of homo- or hetero-complexes with Bak and promoting the release of 
cytochrome c [105]. The release of cytochrome c from mitochondria is critical for 
activation of the intrinsic pathway of apoptosis. This release leads to the formation of 
the apoptosome complex in which caspase-9 is cleaved, subsequently initiate the 
apoptotic cell demise by activation of caspase-3 giving rise to the nuclear apoptotic 
morphology [101] (Figure 1).  
 
 
  9 
2. AIMS OF THESIS 
The overall aim of this thesis was to identify and characterize prognostic biomarkers 
for clinical responses to anti-leukemic treatment in AML and to understand molecular 
signalling mechanism operative for the cellular response to gemtuzumab ozogamicin 
(GO), a targeted therapy of AML. 
Specific aims 
Paper I: To characterize GO-induced cellular and molecular events, linked to 
sensitivity and resistance in AML.  
Paper II: To identify proteins of importance for GO-induced apoptotic signalling 
upstream of the mitochondria focusing on caspase-2, an apical known be involved in 
signalling associated to DNA damage-induced apoptotic signalling. 
Paper III: To identify prognostic biomarkers at gene levels associated with clinical 
long-term response to chemotherapy in a defined AML patient cohort with known 
clinical outcome. 
Paper IV: To identify resistance mechanisms involved in the acquisition of MDR in 
AML patients, using 380 genes chosen by their potential role in MDR reported over the 
past decades and by comparing their expression in AML patient samples collected at 
diagnosis and after recurrent disease.  
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3. PATIENTS AND METHODS 
3.1  PATIENT COHORTS (paper I-IV) 
In the present studies (papers I-IV), AML patient samples taken from biobanked 
material consecutively collected during 1987-2003 and stored at the Dept. of 
Hematology, Karolinska University Hospital Solna, Stockholm, Sweden, was used. The 
studies were approved by the central Ethics Review Board (KI 03-600 (papers I-IV) 
and 2007/1526-31/3(paper II), Karolinska Institutet and followed the declaration from 
Helsinki [106]. 
The samples consisted of peripheral blood collected from adult AML-patients at 
diagnosis, prior to treatment (papers I-III) and at the time of relapse (paper IV). Cells 
were isolated by Ficoll-Hypaque® separation and the mononuclear cells were freshly 
frozen and stored in the biobank. To gain knowledge of the patients’ clinical condition 
and response to treatment approximately 200 medical records and individual patient 
data were collected and reviewed. Some samples were not of sufficient quality, and 
others re-diagnosed to be non-AML, limiting the amount of cases available. Patients 
with acute promyelocytic leukemia (APL) were excluded from these studies (papers I-
IV) due to their specific treatment regimen. Those patients have a chromosomal 
translocation involving the retinoic acid receptor alpha (RARα or RARA) gene and are 
unique from other forms of AML in its responsiveness to all-trans retinoic acid 
(ATRA) therapy [107] [108]. 
Patient characteristics are shown in Table 3. In paper I six patients were analysed, 
five with AML and one with acute lymphoblastic leukemia (ALL). The patient with 
ALL was used as a negative control. In paper II we studied primary AML patient cells 
(n=22), for validation of results obtained from AML cell line in vitro analyses. In paper 
III the gene expression differences in AML patients with poor and good clinical 
outcome were compared. The patients in the training cohort (n=42) were stratified into 
two groups according to their complete remission (CR) duration (i.e. short CR: < 6 
months and long CR: >6 months). In this training cohort the median CR duration was 
161 days, which led us to set the cut-off level for shorter vs. longer CR duration at 6 
months (n=24 and n=18, respectively). The two groups were perceived equal in terms 
of age, sex, white blood cell count, cytogenetic status and presence of preceding 
hematologic malignancy. In this study there were three patients whose diagnosis later 
was revised to ALL. For in silico comparison two independent cohorts were analysed 
and are described in section 3.3.2.  
In paper IV we analysed eleven paired samples (samples taken at diagnosis and after 
relapse) in a patient-to-patient analysis, to compare the gene expression between the 
two time points. Each patient sample here worked as their own control in finding gene 
expression differences after chemotherapy treatment and relapse as compared to the 
time at diagnosis thereby reducing the inter patient heterogeneity.  
All patients in paper III (training cohort) and paper IV had an induction treatment 
with the intention to cure. The chemotherapy consisted of an anthracyclin in 
combination with cytarabine.  
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Table 3. Patient characteristics listed according to the analysis in the different 
papers 











Sex; female 3 15 27 8 
Age (yrs) 61.5 (29-74) 67 (32-85) 62 (18-85) 58 (28-72) 
WBC (x109/l) 59 (1.7-276) 56.8 (2.5-276) 40 (0.9-276) 32.2 (9-32.2) 
Platelets (x109/l) 70 (24-167) 91 (17-303) 65 (8-303) 65 (33-303) 




161 (12-3701) 284.5 (48-
1166) 
OS (days) 480 (140-744) 303.5 (91-
3772) 

















































































Abbreviations; Age: age at diagnosis. WBC: white blood cell count at diagnosis. CR 
dur: complete remission duration. OS: overall survival. Age, WBC, Platelets, CR dur 
and OS are shown as median value (range). FAB-classification: French-American-
British classification of acute leukemia. Intermediate risk (incl *normal cytogenetic 
profile). 
  12 
 
Cell lines (paper I-II) 
The AML cell lines used for experiments in paper I were HL60, NB4 and KG1a, 
described earlier [109] [110] [111]. HL60 and NB4 cells are derived from human 
promyelocytic leukemia cells. KG1a is a cell line of immature myeloblasts, which was 
shown not to respond to colony stimulating factor or to anticancer drugs (e.g. 
daunorubicin and vincristine) [112] and also described by Amico et al., to be resistant 
to gemtuzumab ozogamicin (GO) [113]. In paper II HL60 cells were chosen as model 
system. For molecular studies the AML cells were seeded 24h or 48h prior to treatment 
and were in exponential growth when treated. Cells were incubated with the 
monoclonal antibody gemtuzumab ozogamicin (GO) (described in section 1.5.1) or 
calicheamicin at clinically relevant concentrations (10 to 1000 ng/ml and 0.3 to 30 
ng/ml, respectively) for 24h to 72h. The concentration of calicheamicin used 
corresponds to the amount linked to the antibody (GO 100ng/ml contains 0.3ng/ml 
calicheamicin etc).  
3.3  EXPERIMENTAL METHODS   
3.3.1  Analyses of GO- induced molecular events (paper I-II) 
Cell viability 
The efficacy of GO, calicheamicin and etoposide exposure was characterized by the 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) cell viability 
assay after 24h, 48h or 72h of continuous drug treatment. The MTT assay measures the 
capacity of cells to reduce the MTT to unsoluble formazan, giving a purple colour. The 
formation of the formazon crystals is directly proportional to the number of living cells 
and was measured by spectrophotometer.	   In paper I absorbance was set to 100% in 
untreated cells and viability of the treated cells was determined accordingly. In paper II 
(which also includes daunorubicin), cell viability was analysed after using trypan blue 
stains. In this method non-viable cells will have a leaky membrane and therefore are 
stained blue whereas viable cells, i.e. cells with intact cell membranes are unstained. 
Cells were counted using phase contrast microscopy. Viability prior to treatment was 
set to 100%, to which treated cells were related.  
Apoptosis assessment 
In paper I and II induction of apoptosis after GO or calicheamicin treatment, were 
assessed by analysing nuclear apoptotic morphology. The cells were centrifuged onto 
slides, fixed and nuclei stained using mounting media containing 4´-6´-diamidino-2-
phenyllindole (DAPI). DAPI is a dye that binds strongly to DNA at A-T rich regions. 
DAPI staining of normal cells will give a uniform staining, whereas in apoptotic cells 
fragmentation of DNA will give a punctate staining pattern. Images were acquired on 
fluorescence microscopy (ZEISS Axioplan 2 with a Zeiss x63 lens).  
Mitochondrial dysfunction 
To analyse the GO-induced effects on mitochondrial depolarization in paper I we 
measured the loss of mitochondrial membrane potential using tetramethylrhodamine 
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ethyl ester (TMRE).  TMRE is a lipofilic dye, which ”gets stuck” in the mitochondria if 
the potential is present. If the cell is apoptotic, the mitochondrial membrane looses the 
potential and the dye leaks out of the cell. TMRE-associated fluorescence is measured 
in the Fl-2 channel in flow cytometry and is presented in histograms with peak shifting 
to the left if mitochondria membrane is leaking (i.e. low TMRE staining)	  (paper I). 	  
Activation of the proapoptotic proteins Bak and Bax are central events in apoptosis 
signalling [114] and involves conformational changes in the N-terminus of each of 
them, followed by multimerization.  We examined GO-induced activation of these 
proteins by using antibodies recognizing these activity related conformation changes of 
Bak and Bax respectively (paper I-II), followed by flow cytometry-based 
quantification. In both paper I and paper II activation of caspase-3 was analysed using 
an antibody that recognize the active site, DEVD, of caspase-3 (paper I-II) [98]. The 
antibody used is conjugated to Fluorescein Isothiocyanate (FITC) that allows detection 
by flow cytometry. Activated caspase-3 was quantified and presented as fold change 
mean value as compared to untreated cells, which were set to one. 
Western blot analysis of protein expression 
In paper I and paper II protein expression analysis were performed using western 
blot. Total cell extracts were made and proteins separated using SDS page gels. After 
transfer onto nitrocellulose membranes the membranes were probed with antibodies 
recognizing phosphorylated and total form of p38 MAPK (paper I) and full length and 
cleaved fragments of caspase-2, PARP-1, caspase-3 and Bid (paper II) with GAPDH as 
a loading control. Membranes were incubated with secondary goat-anti-mouse- or goat-
anti-rabbit-antibodies and protein expression were detected using enhanced 
chemoluminescent + method (papers I-II), protein banding intensity quantified by 
Quantity One software. In paper II we also used the Odyssey® Sa Infrared Imaging 
System (LI-COR). Primary AML cells were analysed for expression of caspase-2 
(n=17) and caspase-3 (n=19)(paper II). The loss of patients was due to methodological 
problems.  
Identification of DNA double strand break formation 
In paper II we analysed DNA double strand break (dsb) formation after treating 
HL60 cells with GO, calicheamicin or etoposide using pulsed field gel electrophoresis 
(PFGE). In PFGE, the DNA fragments are separated based on size and hence if DNA 
dsbs are present DNA fragments of lower size are detected. The protocol used was 
optimized for separations of DNA fragments in the size range 1-10 Mbp [115] and data 
in each treatment is presented as fold fragmented DNA (fragments <5.7 Mbp) relative 
to untreated cells.  
The role of caspase-2 in apoptotic signalling 
In paper II we assessed the effects of GO and daunorubicin in cell lines, and the 
effects of GO in primary cells from AML patients, focusing on caspase-2 as a part of 
the apoptotic induction signalling. In order to analyse if GO-induced caspase-3 and 
apoptotic signalling in AML cells were dependent of caspase-2, HL60 cells were pre-
treated with the caspase-2 inhibitor z-VDVAD before chemotherapy treatment (paper 
II). z-VDVAD-fmk is a synthetic peptide that irreversibly binds and inhibits the active 
site of caspase-2 and thereby its function is blocked [116]. After pre-treatment with the 
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caspase-2 inhibitor cells were treated with GO, calicheamicin, daunorubicin or 
etoposide before analysing caspase-3, Bak/Bax activation and cleavage of full length 
Bid into tBid as outlined above.  
Statistical analyses 
Data presented were expressed as the mean values ± standard deviation (S.D.) of at 
least three independent experiments. Significance differences between untreated and 
treated samples were calculated using t-test. For comparison of caspase expression in 
primary AML cells two-tailed Mann-Whitney t-test was applied. 
3.3.2  Gene array analyses: expression and validation (paper III) 
Preparation of RNA and synthesis of cDNA 
In paper III gene expression of AML patient derived cells were studied using 
Affymetrix U133 2.0 Plus GeneChip array (www.affymetrix.com). RNA was isolated 
from mononuclear cells obtained from 42 patients diagnosed with AML using RNA-
Bee (Biosite, Stockholm, Sweden), which is a reagent for isolation of total RNA from 
samples of human origin. The RNA from each patient sample was pooled into two 
groups, short and long CR duration respectively and 500 ng of RNA from each group 
was subsequently transcribed into cDNA using reverse transcriptase. With cDNA as the 
template, in vitro transcription was made to synthesize biotin-labelled cRNA. The 
biotin-label is to ensure a high binding capacity to the chip, using streptavidin antibody. 
RNA was then fragmented in a fragmentation buffer.  
Gene array analysis 
For the gene expression profiling the fragmented cRNA (15 µg/probe array) was 
hybridized to the Affymetrix U133 2.0 Plus GeneChip array in a hybridization oven. 
The chips were washed and thereafter stained using streptavidin phycoerythrin 
conjugate (SAPE) followed by the addition of a biotinylated anti-streptavidin antibody 
and finally with streptavidin phycoerythrin conjugate. Probe arrays were scanned using 
a fluorometric scanner (Affymetrix Scanner) and the generated signal which depends 
on the strength of the hybridization determined by the number of paired bases will 
reflect the degree of mRNA expression. Gene array data chip were normalized using 
the gcRMA algorithm. 
The gene expression data were analysed with GeneSpring G10X software and these 
analyses were made in duplicates. In this software, the unpaired t-test (threshold set to a 
p-value <0.05), “false discovery rate” (FDR) was set to < 5%. For the experiment we 
compared the group with short CR duration to the group with long CR duration. Fold 
change was used for measuring changes in expression levels of each gene (mean value) 
when comparing the two groups. In the subsequent gene analysis we focused on genes 
showing at least a 2-fold (training cohort) difference in gene expression. 
Real-time quantitative PCR 
To validate the gene expression data we assessed the mRNA expression of some 
genes, pooled and individual samples, by real time quantitative polymerase chain 
reaction (RT-qPCR). In this method the mRNA sample is first reversed-transcribed to 
cDNA with reverse transcriptase and then amplified in the presence of a PCR reaction 
  15 
mixture containing primers for the gene of interest, a DNA polymerase (usually Taq 
polymerase), deoxyribonucleotides (dNTP) and a fluorescent DNA-binding dye. To 
compare the expression of genes between different samples in paper III, the 
“housekeeping gene” GAPDH, which has almost a constant level of expression, was 
used for normalization of differences in mRNA content between analysed samples. 
Pooled samples were assessed for four genes shown to be up-regulated (RUNX1T1, 
TKTL1, U2AF1, NUDT4) and three genes found to be down-regulated (ANXA1, 
FLRT3, TLR8) when comparing patients with short CR duration to those with long CR 
duration. The expression of RUNX1T1 was also examined in individual patient 
samples in order to clarify that no single patient sample in the pooled material was an 
extreme “outlier” and thus responsible for the large difference in gene expression. 
Relative quantification was determined by the ΔΔCt formula. For statistical analysis of 
RUNX1T1 in individual patients the Mann Whitney test was applied. 
Ingenuity Pathway Analyses 
To interpret the biological meaning of the gene expression data in the AML samples 
analysed in paper III, the gene expression alterations were subjected to the web-based 
analysis tool Ingenuity Pathway Analysis® (IPA, www.ingenuity.com). IPA is a 
computerized tool that integrates omic data on basis of published prior knowledge 
created in the Ingenuity Knowledge Base. In paper III we specifically used IPA to 
create a custom network which was based on RUNX1T1 in order to find possible 
interaction partners and their regulation in our data set. In IPA, the top gene function 
was detected by Fisher´s Exact Test (threshold p<0.05).  
In silico validation 
In paper III, in silico validation of obtained gene expression results were made using 
publically accessible data sets with gene expression results and corresponding clinical 
data. Via oncomine (www.oncomine.org), published gene expression data was filtered 
for I) cancer form: Leukemia, II) clinical outcome: Survival status, III) platform: 
Affymetrix. Two AML cohorts met this selection, which were used for validation. For 
validation cohort 1 data from Meztzeler et al, which contained 162 AML patients and 
one with refractory anemia with excess of blasts (MDS RAEB), were used [117]. All 
patients had a normal karyotype and patient characteristics contained data on FAB 
classification, age, tissue and overall survival. Validation cohort 2 was obtained from 
Raponi et al, who investigated efficacy and safety of the farnesyltransferase inhibitor 
tipifarnib (FTI) in a single-arm phase-2 study of elderly AML patients (n=34) [118].  
Data included age, gender, unfavourable karyotype and overall survival. Patient 
samples from both cohorts were collected before treatment and consisted of bone 
marrow cells, but also two samples from peripheral blood [117]). In both studies the 
gene array raw data had been uploaded in NCBI Gene Expression Omnibus 
(www.ncbi.nlm.nih.gov/geo), were it was accessible together with individual patient 
characteristics for our in silico validation.  
The gene array raw data from analyses of validation cohorts were downloaded and 
analysed together with the raw data from the training cohort (our own gene expression 
data) using GeneSpring G10X software as described above. In the validation cohorts 
there were no information of CR duration of the patients but the overall survival (OS) 
was known. When analysing the training cohort, a clear association between short CR 
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duration and short OS, was seen as previously been described for AML patients [39]. 
Therefore OS was used as a parameter for prognosis in the validation cohorts where 
patients were divided in two groups according to OS. The cut off was set to the value of 
median overall survival in respective cohort. In validation cohort 1 cut off was set to 
280 days (short OS n=83, long OS n=80) and in validation cohort 2 cut off was set to 
235 days (short OS n=17 and long OS n=17). To ensure that the sample handling or 
differences in the analyses (i.e. preparation of the raw data) were not responsible for the 
observed differences in gene expression patterns, a comparison of gene expression was 
first made within each cohort. The results from each cohort were then compared to each 
other.  
3.3.3  Gene expression of possible multidrug resistance mechanisms (paper IV) 
Preparation of total RNA 
For the gene expression studies of possible multidrug resistance mechanisms in 
AML (paper IV) peripheral blood samples from eleven AML patients were used, 
including samples collected both at diagnosis and at relapse. The total RNA was 
extracted with the Trizol. cDNA was synthesized from 1 µg of total RNA using High 
Capacity cDNA kit  with RNase inhibitor. This kit uses random primers for reverse 
transcription of RNA into cDNA.  
TaqMan Low Density Arrays  
TaqMan Low Density Array (TLDA), which is a highly sensitive and specific 
TaqMan-based RT-qPCR [75], was applied. The choice of 380 genes for analyses of 
chemotherapy resistance was done based on their previously reported role in MDR 
[119]. The genes identified were confined to several different biological mechanisms 
including apoptosis, drug uptake or efflux, tumour transformation, tumour suppressor 
activity, stress response, DNA repair, signal transduction and phase I and II drug-
metabolism [120].  The TLDA card, which is a 384-well custom-made array for the 
380 MDR-associated genes, were thus used in which cDNA were mixed with the 
TaqMan Universal PCR Master mix, then loaded into reaction reservoirs and 
centrifugally spread into each reaction chamber.  
Data analyses 
Collected data from TLDA (i.e. the eleven paired AML samples) were analysed 
using BRB ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.html), a method 
developed for visualization and statistical analyses of microarray gene expression data. 
To focus on genes that are more likely to be informative, genes were filtered out if they 
were expressed in less than 50% of the samples.  
Statistical analysis (paper IV) 
For correlation to FAB-classes and for the expression of each genes, Spearman rank 
test with the threshold p <0.05 was applied and for correlation of gene expression with 
the CR duration, data were subjected to a Cox proportional Hazards test. False 
Discovery Rate (FDR) for each gene was calculated using the Benjamini-Hochberg 
method. Pairwise comparisons were manually performed using the ΔΔCt method [121].  
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4. RESULTS  
Treatment with high dose chemotherapy often leads to severe side effects that 
sometimes are even lethal. At the same time, we aim at reaching a better long-term 
effect and need to kill remaining leukemic cells, in order to cure. With current available 
treatment options, this is only reached for a minority of the patients and most of them 
will have a recurrent disease within 1-2 years. In papers I and II we investigate the 
targeted therapy gemtuzumab ozogamicin (GO), where the precise cellular and 
molecular mechanisms behind the clinical response of GO treatment remain rather 
vague. However, a more specific knowledge of the mechanisms of cell death induced 
by GO could pave way for identification of possible molecular determinants for in vivo 
GO responsiveness and help to reveal AML patients, for whom GO may be of value as 
treatment. The high amount of relapse in AML is a large problem, why the need of 
improved prediction of chemotherapy response and knowledge of resistance 
mechanisms in AML, is necessary. Predictive biomarkers for response and response 
duration are required and mechanisms for therapy resistance need to be identified. 
These research issues were in focus in paper III and paper IV, respectively. 
 4.1  PAPER I  
Deficient activation of Bak and Bax confers resistance to gemtuzumab 
ozogamicin-induced apoptotic cell death in AML 
In paper I, we focused on proapoptotic mitochondrial mediated signalling induced 
by GO. Initially, cells were incubated with GO or free calicheamicin in clinically 
relevant doses (10 to 1000 ng/ml and 0.3 to 30 ng/ml, respectively) showing a clear 
dose and time dependent decrease in cell viability in GO-sensitive cell lines (HL60 and 
NB4), as compared to untreated cells. In contrast, this was not the case in the KG1a cell 
line, which is GO resistant, although KG1a cells responded with decreased cell viability 
when treated with etoposide, another DNA-damaging agent.  
Since the active part of GO, calicheamicin, causes site-specific DNA dsbs [122], 
which may induce apoptosis through the intrinsic apoptotic pathway, we examined 
activation of the mitochondrial pathway after GO administration. Activation of 
mitochondria is an early apoptotic event in which cytochrome c is released and the 
apoptosome is formed, resulting in activation of caspase-9 and subsequently of 
caspase-3 (Figure 1) [114] [87]. We observed that GO induced depolarization of 
mitochondria and activation of caspase-3 in the sensitive HL60 cells, while no such 
event was observed in GO-resistant KG1a cells. Similar activation was revealed using 
free calicheamicin or etoposide. In contrast, GO-resistant KG1a cells did not reveal the 
activation of caspase-3 after GO-exposure. A 2-fold increase in active caspase-3 was 
however observed in KG1a cells when exposed to clinical relevant doses of either 
calicheamicin or etoposide, showing that activation of caspase-3 is functional in KG1a 
cells. The results suggests that GO and calicheamicin activate the intrinsic pathway for 
apoptosis in GO sensitive cells.  
Conformational changes in Bak and Bax leading to their proapoptotic status are 
central in mitochondria-mediated apoptotic signalling and precede depolarization of 
mitochondria [114] [123]. Using antibodies recognizing the specific activity-related 
conformational changes in Bak and Bax, we examined the activation of those proteins 
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[124] [125]. Importantly, activation of Bak and Bax in response to GO was found in 
GO-sensitive HL60 cells increasing sixfold and fourfold respectively, when treated 
with GO 1000 ng/mL. Treatment with calicheamicin gave similar results regarding 
both Bak and Bax, whereas in GO-resistant KG1a cells neither GO nor calicheamicin 
were able to induce Bak/Bax activation.  
DNA damage-induced apoptosis has been linked to a persistent activation of the 
stress-activated protein kinases (SAPKs) such as p38 MAPK [126]. We found that 
there was a dose-dependent increase in activation of p38 MAPK in GO-sensitive HL60 
cells, with as much as a fourfold increase at the highest GO concentration whereas in 
GO-resistant KG1a cells no GO-induced activation of p38 MAPK was observed. Thus, 
our results suggest that activation of p38 MAPK is induced in GO-induced mediated 
cell kill.  
We also analysed GO-response in primary AML cells and found that in CD33-
positive blast cells derived from a treatment naïve AML patient, both GO and 
calicheamicin treatment resulted in approximately 30-50% reduced cell viability after 
48h. In contrast, in CD33-positive cells from a heavily pre-treated AML patient in 
relapse, neither GO nor calicheamicin were capable of inducing any cytotoxicity. 
Moreover, cells from the ALL patient (in 2nd relapse) also failed to respond to GO 
treatment, but were inhibited by calicheamicin. In conclusion, our results from GO-
treated primary AML cells and AML cell lines pinpoint the importance, not only of 
CD33 expression but also of p38 MAPK activation with subsequent initiation of 
mitochondrial depolarization and caspase-3 activation, as molecular determinants for 
clinical GO responsiveness in GO-sensitive cells. 
4.2  PAPER II  
Caspase-2 is a mediator of mitochondria-independent apoptotic signaling in 
response to gemtuzumab ozogamicin in acute myeloid leukemia  
In paper II we aimed at understanding GO-induced apoptotic signalling up-stream 
of the mitochondria. As caspase-2 is known to play a role in DNA-damaging apoptotic 
signalling at this level [127], we focused our analysis on how it acts in GO-induced cell 
death signalling. By treating HL60 cells with GO (100 ng/mL and 1000 ng/mL) during 
24h, using immunoblotting and GAPDH as a loading control, we demonstrated that GO 
triggered full-length caspase-2 cleavage to a 35 kDa cleaved fragment. Importantly, 
also in primary cells from three AML patients, treated with GO we showed that full 
length caspase-2 disappeared albeit no cleavage fragment was evident.  
In paper I we showed that caspase-3 is required for GO-induced apoptotic signalling 
in AML. In this paper we showed that caspase-2 inhibition by the caspase-2 inhibitor z-
VDVAD-fmk blocked both GO- and calicheamicin-induced caspase-3 activation in 
HL60 cells. Thus, we demonstrated that caspase-2 plays a role in GO-induced apoptotic 
signalling and at least in part acts upstream of caspase-3. Since daunorubicin represents 
one of the standard chemotherapy drugs in AML treatment, we wanted to know 
whether it affects the same apoptotic signalling as was shown for GO. In HL60 cells we 
observed that proliferation was blocked, induction of apoptosis was induced and 
activation of caspase-3 was increased after 48h daunorubicin treatment (100 and 
500nM). Unlike in the experiments above, HL60 cells subjected to daunorubicin in 
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combination with the caspase-2 inhibitor z-VDVAD-fmk, did not show a statistically 
significant reduction of caspase-3 activity, only a slightly reduction. This suggests that 
daunorubicin-induced apoptosis does not include activation of caspase-2 but involves 
caspase-3 activation through an alternative path. 
As been shown earlier, the Bcl-2-family members Bak and Bax are important for 
mediating apoptosis through mitochondrial pathway [114] and we found in paper I that 
GO-treatment causes increased Bak and Bax activation in GO-sensitive cells but not in 
resistant AML cells. We therefore examine if caspase-2 is essential for Bak/Bax 
activation (Figure 1). 
Importantly, we found that inhibition of caspase-2 activity with z-VDVAD-fmk did 
not affect activation of Bak and/or Bax after GO treatment and appeared, accordingly, 
not to induce mitochondrial depolarization. The same finding was observed when GO 
was replaced by calicheamicin, etoposide or daunorubicin. Thus, at least in these AML 
cells caspase-2 signalling in response to these drugs is via a non-Bak/Bax mediated 
route to caspase-3. Another Bcl-2-family member, Bid, is a BH3-only protein which is 
exclusively cytosolic in living cells and is cleaved during apoptosis into a truncated 
form, tBid, which subsequently translocates to the mitochondria [128] were it regulates 
Bax relocalization to the mitochondria leading to cytochrome-c release [129] [130]. By 
studying GO-induced Bid activation and the possible involvement of caspase-2, we 
found a dose-dependent decrease of full-length Bid after treatment with GO. 
Importantly, blocking caspase-2 only caused a slight reduction in Bid cleavage, hence 
we cannot see any clear role of this caspase in Bid processing after GO treatment. Thus, 
our data indicate that there are at least two pathways that are activated in AML cells in 
response to DNA-damaging agents, one involving Bak/Bax activation and another 
involving caspase-2 both which are of importance for implementing of apoptosis via 
caspase-3 in response to these agents (Figure 1). 
We next analysed signalling events upstream of Bak/Bax and caspase-2 activation. 
For that purpose pulsed field gel electrophoresis (PFGE) was used to analyze DNA 
double strand breaks (dsbs), which are thought to be critical for the cytotoxic effect of 
GO. Calicheamicin has been reported to cause DNA dsbs [122] yet the involvement of 
DNA dsb in response to GO at clinically relevant doses remained elusive. In line with 
previous results we observed that free calicheamicin, already after 4h showed a 10-fold 
increase in formation of DNA dsbs, which remained also after 24h. After GO treatment 
we observed a 2-fold higher level of DNA dsbs at 24h but with no major increase at 1h 
or at 4h. This suggests that GO at clinically relevant doses does indeed induce DNA 
dsb, an event that coincides with caspase-2 activation. 
In addition, to cause DNA dsbs, GO responsiveness has also been linked to 
induction of G2 arrest in AML cells [113]. In line with previous reports we found that 
GO treatment during 24h resulted in an accumulation of 14% of the HL60 cells in 
G2/M-phase (compared to 5% of the untreated cells). Importantly, analysing the role of 
caspase-2 in this context showed that inhibition of caspase-2 activity with z-VDVAD-
fmk did not alter the cell cycle distribution. Therefore, our results suggest that to affect 
the cell cycle arrest due to DNA damage induced by GO, the catalytic activity of 
caspase-2 does not seem to be required. Thus, caspase-2 seems to be required only for 
apoptotic signalling. 
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To reach and maintain complete remission (CR) are important features for the 
clinical outcome in AML. In an attempt to place these cell line-derived results in a 
clinical context, we also analysed the expression of caspase-2 and caspase-3 in blast 
cell populations isolated from 22 AML patients, from the above-mentioned patient 
cohort, at the time of diagnosis, prior to therapy. Full-length caspase-2 (n=17) and 
caspase-3 (n=19) were examined in mononuclear cells and the patients were divided 
into two groups according to CR duration (short CR <6 month and long CR >6 month). 
Caspase-2 or caspase-3 protein expression varied among patients, with a greater spread 
in the group with long CR duration. Caspase-3 did not show any differences in 
expression while for caspase-2 we observed a higher amount in patient with long CR 
duration. However, an analysis of a larger patient cohort including full length and 
cleaved caspase-2 could likely better clarify if caspase-2 expression is divergent already 
at diagnosis. Such analyses are on the way. 
In conclusion, we demonstrated that GO caused a cleavage of caspase-2 in GO-
responsive AML cells but not in GO-resistant AML cells. Thus, caspase-2 has a critical 
role in the intracellular cell death signalling after GO treatment in AML cells. Our 
results suggest that caspase-2 probably works in a pathway separate from the intrinsic 
pathway, leading to activation of caspase-3, as blocking of caspase-2 did not alter the 
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 4.3  PAPER III  
Gene expression analyses at time of diagnosis indicate biomarkers predictive of 
therapeutic response in acute myeloid leukemia  
In paper III we aimed to identify biomarkers predictive of clinical response in AML.  
For that purpose we isolated mRNA from diagnostic samples from 42 AML patients  
(“training cohort”) which were subjected to Affymetrix® gene expression analysis 
(Figure 2). All patients entered CR after high-dose induction chemotherapy, reaching a 
median CR duration of 161 (range 12-3701) days. Samples from patients with “short 
CR duration” (<6 months, n=24) and “long CR duration” (>6 months n=18), 
respectively, were pooled together and a comparison of gene expression in these 
cohorts was examined.  
  
 
Figure 2: Workflow of gene expression analysis in AML patients (n=42) 
 
We found a clear difference in gene expression at diagnosis in AML patients, when 
comparing the two clinically different groups and analyses revealed 383 genes to be up-
regulated and 610 genes down-regulated more than two fold in samples from patients 
with short, as compared to those with long CR duration. Out of these genes the most 
prominently regulated was runt-related transcription factor 1; translocated to 1 (cyclin 
D-related) (RUNX1T1), which was up-regulated 116 fold in patients with short CR 
compared to those with long CR. The Ca2+-dependent phospholipid binding protein 
Annexin 1 (ANXA 1) was down-regulated 58 fold in the same comparison.  
We next validated the observed gene expression alterations with RT-qPCR and 
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could show that RUNX1T1, TKTL1, U2AF1 and NUDT4 all had a higher expression 
in patients with short CR duration, compared to those with long CR duration, whereas 
ANXA 1, FLRT3 and TLR8 were expressed at lower levels. Next we wanted to ensure 
that no single patient was behind the observed large up-regulation of RUNX1T1 in the 
group with poor responders and therefore we examined RUNX1T1 mRNA expression 
in individual AML patient samples in each group (Figure 3). Albeit RUNX1T1 mRNA 
expression varied among the individual patients a significantly higher transcript levels 
of RUNX1T1 were confirmed in the poor outcome group when performing RT-qPCR 






















Figure 3:  RT-qPCR analysis of RUNX1T1 gene expression in individual patient 
samples (n=20). Loading control: GAPDH. Statistical analyses: Wilcoxon rank-sum 
test. ***p=0.0002. 
 
To identify potential signalling networks and their respective functions associated 
with these top up- or down-regulated genes in the short CR duration group of AML 
patients and their respective functions, IPA network analysis was carried out. The top 
functions revealed were cell death, developmental disorders, genetic disorders, 
metabolic disorders, cancer and haematological disease. We next focused on 
RUNX1T1 and applied IPA to reveal putative interaction partners. Interestingly, we 
found that most of its interacting partners were transcription factors and one of these 
was transcription factor 3 (TCF3), which indeed was found to be up-regulated in 
patients with short CR duration (5 fold). Another partner of RUNX1T1 with a higher 
expression in poor responders was the cluster of differentiation molecule 34 (CD34), 
which showed a 3 fold up-regulation. CD34, a cell surface antigen, is reported to be 
selectively expressed on both normal and leukemic human hematopoietic progenitor 
and stem cells [131] [132] and is also been demonstrated to be a predictor of poor 
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prognosis in NPM1-positive AML patients [133] [134]. Moreover, an association 
between CD34 expression and the expression of multidrug resistance gene (MDR1) has 
been revealed [135], and is suggested to be a contributing factor to the reason for the 
adverse prognosis in CD34-positive AML patients [136].  Thus, with network analyses, 
we found that RUNX1T1 indeed was associated with a number of transcriptional 
regulators and of these TCF3, also was up-regulated in AML patients with short CR 
duration. 
To validate our gene expression results in independent patient cohorts we made an 
in silico comparison of two larger AML patient cohorts. For the in silico validation, 
training and validation cohorts were analysed using GeneSpring GX10 software 
comparing patients with poorer to those with better outcome. Comparative analysis was 
performed in each group (i.e. patients with short CR duration/OS vs. long CR 
duration/OS) and the results from each group were then compared with the results from 
the other groups in terms of up- or down-regulated genes. To gain a suitable amount of 
regulated genes we chose to set the cut off to 1.3 fold. These analyses resulted in 52 
genes, which were found to be regulated in all three cohorts (Figure 4).  
 
Figure 4:  Venndiagram showing regulated genes in each cohort, respectively. The 
training cohort gene array results from pooled patient samples (n=42), validation 
cohort 1 gene expression results from Metzeler et al [117] (n=163) and validation 2 
gene expression results from Raponi et al [118] (n=34).  Cut off set to 1.3 fold. From 
the similarly regulated genes from all three cohorts further stratification were done 
according to cancer, leukemia, apoptosis and proliferation and revealed four genes (to 
the right).   
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Reducing the analysis to genes previously reported to be involved in cancer, 
leukemia, apoptosis or proliferation made further limitations of the genes. With this 
approach we ended up with three genes, Chemokine (C-X-C motif) ligand 3 (CXCL3), 
Zinc finger, MIZ-type containing 1 (ZMIZ1) and TCF3 up-regulated and Peroxiredoxin 
2 (PRDX2) down-regulated in the group with poorer prognosis. CXCL3 expression has 
previously been shown to be increased in colon cancer, as compared to normal tissue 
and were demonstrated to be higher in patients with local versus systemic disease 
[137]. Given that we see a higher expression in patients with short CR/OS, we 
hypothesize that high expression of CXCL3 in leukemic blast cells may improve 
development and maintenance of leukemia. ZMIZ1 is a transcriptional coactivator of 
the protein inhibitor of activated STAT (PIAS) family of proteins [138]. Its role in 
oncogenesis is unknown. Rakowski and colleges, however, have shown that ZMIZ1 
functionally interacts with NOTCH1 to promote transcription and activity of c-MYC 
and that silencing of ZMIZ1 delayed tumor growth and increased apoptosis in a T-ALL 
cell line [139]. The function of ZMIZ1 in AML is unclear, but our results are in line 
with the findings of Rakowski et al, since ZMIZ1 was up-regulated in all three cohorts. 
TCF3, one of the transcription factors that interact with RUNX1T1, was found to have 
a slightly increased expression in patients with poorer prognosis also in validation 
analysis. In colorectal cancer cells overexpression of TCF3 has been shown to repress 
induction of Wnt signalling which subsequently leads to increased proliferation [140]. 
This is in line with our observation demonstrating a higher expression of TCF3 in AML 
patients with poor prognosis, which would possibly lead to an increased proliferation of 
leukemic blast cells. PRDX2 is a gene with an antioxidant function in cells [141] and 
has interestingly been identified as a tumour suppressor gene with reduced expression 
in AML [81]. In validation of our results we found PRDX2 to be down-regulated in all 
three cohorts albeit to different degree. 
Analyses of overall survival in relation to mRNA expression of selected genes 
(CXCL3, ZMIZ1, TCF3 and PRDX2) were conducted (Validation cohort 1) by 
dividing the patients according to high or low gene expression. Cut off were set to the 
median value of gene expression and survival data added to Kaplan-Meier plot. 
Regarding ZMIZ1, we found a significantly shorter survival in patients with higher 
ZMIZ1 expression (p=0.03), which could not be shown in relation to CXCL3. In 
contrast, TCF3 showed a lower expression in patients with poorer prognosis. There was 
no difference between low or high expression of PRDX2 regarding survival.  
All in all, our results show that by analysing gene expression in AML patient 
samples according to clinical outcome, one may indeed identify gene expression 
alterations which could hold biomarker potential of CR duration in this tumour 
malignancy. Thus, we showed that three genes, CXCL3, ZMIZ1, TCF3, involved in 
tumour genesis were up-regulated in patients with poor prognosis and that one gene, 
PRDX2, associated with tumour suppression was down-regulated in the same group of 
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 4.4  PAPER IV  
Multidrug Resistance in Relapsed Acute Myeloid Leukemia: Evidence of 
Biological Heterogeneity  
A major challenge in treating AML is resistance to chemotherapy. Multidrug 
resistance (MDR) is achieved when a single drug treatment causes the development of 
resistance to other unrelated drugs [73] and MDR is thought to be one mechanism 
behind drug resistance of AML [74] [142] [143].  In this study we wanted to assess 380 
genes, chosen based on their potential role in MDR, in paired samples (at diagnosis and 
after relapse) from AML patients. The methods used is shown in Figure 5.  
 
 
Figure 5: Methods used in paper IV. Paired samples from 11 patients (at diagnosis 
and at time of relapse). TLDAs: TaqMan Low Density Arrays, MDR: multidrug 
resistance, BRB ArrayTools: a microarray-data statistical analysis tool. 
 
Taken into account that AML is a heterogeneous disease the interpatient variation 
was reduced by making a patient-to-patient analyses of diagnosis and relapse sample. 
By this approach the risk of false hits, which is related to AML heterogeneity, was 
decreased. "Unsupervised hierarchical clustering" showed that 6 out of 11 paired 
samples were grouped together suggesting that the resistance development was not 
likely caused by a major genetic change between the different time points. In contrast, 
the other five patients had a large heterogeneity in their gene expression observed in 
paired samples suggesting that the leukemic blasts at relapse had a different origin 
compared to at diagnosis. Moreover, in samples that clustered apart there was not any 
trend when correlated to FAB-classification, treatment, CR duration or OS, which may 
be due to the heterogeneity of the disease or to a small number of patients analysed.    
To find out whether the MDR genes are reflecting the maturation stage of the AML 
cells, we correlated diagnostic samples with FAB class (M0-M5), which reflects the 
degree of maturation of the leukemia cells. Interestingly, this revealed that 52 out of 
331 genes were significantly associated to FAB. Bcl2-related protein A1 (BCL2A1) 
and glutathione reductase (GSR) were two genes (p<0.05 and FDR <15%) in which 
gene expression was increasing with the maturation of the cells, i.e. correlated to FAB 
class M0 to M5. Moreover, four genes showed a negative correlation with high 
expression in immature cells compared to more differentiated cells i.e. DNA 
polymerase eta (POLH), H/ACA snoRNPs (small nucleolar ribonucleoproteins) gene 
family (NOLA2), ATP-binding cassette sub-family D member 4 (ABCD4) and CDK-
activating kinase assembly factor MAT1 (MNAT1). As CR duration is of importance 
for prognosis and survival in AML, we also correlated diagnostic samples to CR 
duration. Out of the 331 genes examined 38 genes were significantly correlated with 
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CR duration but none of them reached FDR <15% possible due to a low number of 
patients.  
 
Figure 6: Overview of analysis in paper IV, according to analysis made from 
diagnostic samples or from paired samples (i.e. diagnostic and relapse sample). 
 
Interestingly, analysis of paired (patient-by-patient) samples revealed that each 
patient had a unique gene signature likely reflecting that diverse resistance mechanisms 
are potentially operative in different AML patients. Focusing on nine ABC transporters 
which previously has been shown to mediate a MDR phenotype in other tumour types 
[73] [144] [145], we found that all patients except one, expressed an increase of at least 
one ABC transporter, at time of relapse. Importantly, these transporters were capable of 
transporting anthracyclines, vinca-alkaloids or both [146] [77]. Furthermore, one 
patient was found to have an overexpression of four ABC transporters i.e. ABCB1, 
ABCC1, ABCC5 and ABCG2 indicating that chemotherapy including anthracyclines 
or vinca-alkaloids will probably not benefit this patient [73]. In conclusion, we found 
that six patients out of 11 showed a similar MDR associated gene expression pattern at 
diagnosis and relapse suggesting that the same leukemic clone may be responsible for 
relapse. In contrast, in the other 5 patients analysed, the MDR-linked genes showed 
great difference at diagnosis and relapse indicating that in this subset of AML patients, 
a MDR phenotype may be driven by altered expression of one or several different ABC 
transporters. Our results indicates the importance of making repeated analyses of gene 
expression in order to consider further treatment for each individual patient. 
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5. DISCUSSION AND FUTURE PERSPECTIVES  
 5.1  PAPER I-II  
Apoptotic signalling include intrinsic and extrinsic pathways as a response to GO 
treatment in AML cells  
GO has recently attracted renewed interest as a targeted therapy for AML. The 
specific cellular and molecular mechanisms induced by GO treatment in AML are not 
fully understood and further analysis may help us to understand. Therefore we analysed 
response to GO-induced apoptotic signalling in AML cell lines and patient-derived 
AML cells treated in vitro. Primary AML cells were analysed to verify that the results 
from cell line analyses were also relevant in patient cells and for which AML patient it 
may be of value, thereby making translation of our in vitro findings into clinic. In 
conclusion we demonstrate that GO induce activation of caspase-3, Bak/Bax and p38 
MAPK in GO-sensitive cells but not in GO-resistant cells (paper I). Focusing on the 
role of caspase-2 in GO or daunorubicin induced apoptotic signalling we show that GO 
cause caspase-2 cleavage into active fragment (paper II). When blocking caspase-2 we 
demonstrated a decrease of caspase-3 activation in GO-sensitive cells (paper II). Thus, 
our results implicate that CD33 expression, DNA damage signalling and repair, pro-
apoptotic pathways as well as p38 MAPKs are involved in the sensitivity and resistance 
to GO and other chemotherapies of AML. Below are some reflections of these findings 
and future directions on how our findings may be of value for novel therapeutic 
strategies for AML. 
In paper I, we demonstrate that HL60 cells and CD33-positive primary cells isolated 
from AML patients at diagnosis, showed a clear dose- and time-dependent effect of 
both GO and calicheamicin alone at clinically relevant doses (10 to 1000 and 0.3 to 30 
ng/ml, respectively). The necessity of AML blast cells to express CD33 in order to 
respond to GO treatment has been discussed before. Although it would be reasonable to 
believe that the CD33-positive cells would be more sensitive to GO in contrast to 
CD33-negative cells, Boghaert and colleagues showed that an accumulation of a 
conjugate of anti-CD33 and calicheamicin in human tumour xenograft in nude mice, in 
the absence of detectable amounts of targeting antigen, led to sufficient accumulation 
of the drug to inhibit tumour growth of 10 different CD33-negative xenograft models 
[147]. Other in vitro studies have also revealed a direct relationship between CD33 
expression and GO-induced cytotoxicity [148]. Data obtained from correlative studies 
conducted within the context of GO clinical trials for adult relapsed AML, are 
suggesting that CD33 expression may be associated with other AML prognostic factors 
[89] [149]. All in all our results and others correspond with the notion that the clinical 
effect of GO treatment for AML patients, in sufficiently high doses, cannot fully be 
linked to the degree of CD33 positivity in individual leukemic cell populations [89] 
[90] [150]. 
The results on GO presented in this thesis, as well as with daunorubicin illustrates 
that failure to activate pro-apoptotic signalling at mitochondria could impart 
chemotherapy response of AML. When the pro-apoptotic effector proteins Bak and 
Bax are activated they form pores in the outer mitochondrial membrane leading to 
mitochondrial outer membrane permeabilization and release of cytochrome C that 
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promotes caspase activation [114] [151]. In paper I we showed that a functional GO-
induced apoptotic response involved proper activation of Bak and Bax in GO-sensitive, 
but not in GO-resistant KG1a cells. Thus in paper I, we speculate that one resistance 
mechanism of GO may be located up-stream of Bak/Bax. In order to find a protein 
responsible, or in part responsible for this activation, one way is to further analyse the 
BH3-only protein Bid and its truncated form (tBid). BH3-only proteins are known to be 
part of the activation of Bax and communicating in both the extrinsic and intrinsic 
pathway. To perform pro-apoptotic function, BH3-only protein requires the presence of 
Bak and Bax proteins [99]. In paper II we demonstrated a decrease of full-length Bid in 
response to GO treatment, but further analyses are needed including simultaneously 
assessment of the tBid increase and Bax activation to reveal if tBid is instrumental in 
causing GO-induced Bax or Bak activation. The Bcl-XL prevents apoptosis in 
hematopoietic cells [152] and is reported to be abundantly expressed in both 
megakaryocytes and erythrocytes [153]. Moreover, one may speculate that Bcl-XL 
could function by binding to activated Bak and Bax so that they can no longer 
oligomerize [99] [154].  
Moreover, it would therefore be interesting to further analyse Bcl-XL in AML cells 
lacking Bid cleavage and activation of Bak/Bax, to reveal if Bcl-XL could imparting on 
these events. A high expression of Bcl-XL may also include a simultaneous block of 
caspase-2 induced apoptosis as previously been reported [155]. In the context of our 
findings on GO-induced caspase-2 cleavage it would therefore also be interesting to 
analyse if Bcl-XL in this aspect, also in our AML patient material, may be linked to 
caspase-2 expression and CR duration in the clinical setting.  
Gemtuzumab ozogamicin (GO) is a remarkable therapeutic agent that is not yet 
easily available on the market. Although a multitude of clinical and molecular studies 
have been performed, there is still no unequivocal evidence regarding the benefit-risk 
ratio of this drug. Our results on GO-induced signalling in vitro support that there are 
patients clearly sensitive to GO and who probably would benefit from this treatment.  
Our apoptosis signalling data may help to further select these patients.  
 
 5.2  PAPER III-IV  
Gene identification of CR duration biomarkers and multidrug resistance 
mechanisms in AML patients based on gene expression analyses  
AML is a highly heterogeneous disease and the effectiveness of chemotherapy in 
AML varies among individual patients. In the last decades rapid development in omic 
technologies i.e. gene expression, proteomic profiling and DNA and/or RNA 
sequencing development as well as in computerized bioinformatics tools enable a 
global analysis of molecules aberrations. Thus, it has become possible to link certain 
molecular feature of an individual patient tumour to treatment response and in this way 
allow a more tailored treatment approach as exemplified by the presence of 
t(15;17)(q22;q12) in APL, where the patients are treated according to specific 
guidelines due to a superior treatment response. Unfortunately, AML biomarkers that 
could guide treatment remains to be elucidated.  
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In an attempt to identify such biomarkers that are significantly associated with 
remission duration in AML, we analysed gene expression followed by pathway 
analysis (paper III). We found that gene expression varies widely between the AML 
patients with short and long CR duration. In pooled cell samples from patients with 
short CR duration, as compared to those with long, gene array analysis revealed 10 
genes to be up-regulated and 5 genes down-regulated >30 times. The transcription 
factor gene RUNX1T1, located on chromosome 8q22, was the most prominently up-
regulated (x116) in the group with the short CR duration as compared with long CR 
duration. RUNX1T1 is known to be activated in AML including the M2 subtype and 
chromosomal translocations involving this gene are well documented in AML [3]. Thus 
one of the most frequently observed cytogenetic aberrations in AML is 
t(8;21)(q22;q22), which involves a fusion between RUNX1T1 and RUNX1 which give 
rise to a fusion protein [156]. Patients with this specific translocation have been 
considered to have low risk leukemia, according to cytogenetic aberration [22]. In our 
study we found only three patients expressing this translocation. Still, RUNX1T1 was 
markedly, highly up-regulated in patients with poorer prognosis. It is tempting to think 
that a high expression of RUNX1T1, without this specific translocation (i.e. t(8;21)), 
may have other effects on cell signalling or development and maintenance in AML. 
Thus, we know that RUNX1T1 interact with DNA-bound transcription factors and 
recruit co-repressors, such as mSin3, N-cor, HDAC1, to facilitate transcriptional 
repression [157]. With this knowledge, one can speculate that there may be other 
interactors, such as tumour suppressor genes, where RUNX1T1 can contribute to 
increase the transcriptional repression and thereby accelerate tumour growth or 
proliferation.  
In IPA we analysed networks focusing on RUNX1T1. Interestingly, among the 
interacting partners of RUNX1T1, we found that most of them were transcription 
regulators. As a controller of the flow of genetic information from DNA to mRNA, 
transcription factors may be of importance in the gene expression of leukemic cells. In 
our study IPA revealed TCF3 as one of the interacting partner of RUNX1T1 and was 
also slightly up-regulated in training and validation cohorts. In breast cancer, Slyper et 
al, observed that expression of TCF3 was linked to poor tumour differentiation in basal-
like subtype, and that high TCF3 levels were significantly associated with poor survival 
[158]. Moreover, as a repressor of Wnt signalling target genes, TCF3 is suggested to 
block the ability of butyrate to enhance Wnt activity and therefore contribute to 
colorectal cancer cell tumour genesis [140]. Further analysis of TCF3 is therefore 
warranted. 
Mutation analyses have an enormous dynamic evolution when it comes to analyses 
of AML relapse [159]. Walter and colleagues discusses that myelodysplastic syndrom 
evolving into AML are driven not only by recurrent mutations from founding clones 
but also from the daughter subclones [159]. In RUNX1 (i.e. a translocation partner of 
RUNX1T1), seven acquiring novel mutations has been demonstrated in de novo AML 
with non-complex karyotype, associated with an unfavourable prognosis [160] and 
linked to chemo therapy resistance [161]. When studying the benefit and clinical 
relevance of RUNX1 as a marker for residual disease, Kohlmann and colleagues 
described a smaller subset of patients in relapse were the initial mutation was not 
detected but in which the occurrence of a novel mutation of RUNX1 was evident [162]. 
This may be due to an evolution of a novel resistant clone. Albeit mutations in 
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RUNX1T1 is not described in AML, there a few reports of somatic mutations in other 
cancers, such as breast-, lung- and colon cancer, suggesting these mutations to have 
functional effects and may function as oncogenes [163] [164]. Hence further studies in 
RUNX1T1 in AML are encouraged.  
In validation of the gene expression from the training cohort, we could not verify the 
high expression of RUNX1T1 in patients with poor prognosis. This may be due to a 
small number of patients or possible the lack of subgroup analysis. Interestingly, we 
found 52 genes regulated in all three cohorts and of those four genes aroused a special 
interest according to their reported involvement in cancer, leukemia, apoptosis or 
proliferation. One of the identified genes was CXCL3. CXCL3 is a member of the 
growth-related oncogenes (GRO) and binds to a receptor, CXCR2 [165]. CXCL3 has 
previously been described in whole blood from healthy donors [166] and the blood 
cells were also the main synthesis sites of its receptor CXCR2 [166]. However, CXCL3 
has previously only been connected to solid tumours. Thus in patients with colon 
cancer, an increased expression of CXCL3 as compared to normal colon tissue was 
described, and it was shown that the CXCL3 expression level was significantly higher 
in patients with local versus systemic disease [137]. Doll and colleagues also suggested 
that CXCL3 together with other chemokines (e.g. IL-8) accompanies the induction of 
metastasis in colorectal cancer, but might not be necessary for maintenance of the 
metastatic disease [137]. Moreover, in estrogen receptor-α positive breast cancer, high 
expression of CXCL3 was correlated to significantly shorter relapse-free survival 
[166]. As in the former situation, we observed an up-regulation of CXCL3 in AML 
patients with poorer prognosis, but the effect of CXCL3 in AML still needs to be 
elucidated.  
Another gene we found to be up regulated was ZMIZ1. ZMIZ1 is reported to 
contribute to c-MYC activation and oncogenesis by collaboration via activated 
NOTCH [139]. c-MYC function is essential for proper haematopoiesis as it regulate the 
balance between self-renewal, differentiation and proliferation that is required for blood 
formation. Interestingly, c-MYC is reported to have an increased expression in certain 
cases of AML where it is thought to interrupt the balance in haematopoiesis leading to 
increased proliferation and simultaneous blocking terminal differentiation [167]. In our 
study we observed higher expression of ZMIZ1 in patients with poorer prognosis. Due 
to earlier described activation of c-MYC and collaboration ZMIZ1-NOTCH, one can 
imagine that silencing of ZMIZ1 could have an impact even in AML blast cells slowing 
tumour growth and increasing apoptosis as described in T-ALL cells [139]. Analyses 
on AML cells still need to be performed, but one can think that, if this is true for AML 
cells, there is a possibility to use ZMIZ1 inhibitors as a part in the treatment of AML.  
The only gene that we found in paper III to have a decreased expression in AML 
patients with short CR/OS was PRDX2, an antioxidant that acts as an inhibitor of 
myeloid growth [168] [81]. Agrawal-Singh et el, has described PRDX2 as a tumour 
suppressor gene, as a low expression level was clinically associated with poor 
prognosis in AML [81]. Histone acetylation and DNA methylation patterns are marks 
that ensure accurate transmission of chromatin states and gene expression patterns and 
their interplay may involve gene silencing in tumours [82]. Arawal-Singh et al, have 
investigated the histone H3 acetylation in several loci in the AML epigenome and 
found that PRDX2 was silenced by epigenetic mechanisms as a consequence of DNA 
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hypermethylation and loss of H3 acetylation at the promoter region [81]. A role for 
PRDX2 as a tumour suppressor gene is in line with our findings where significantly 
lower expression of PRDX2 was found in patients with poor prognosis. Interestingly, it 
is suggested that PRDX2 act as a growth suppressor in leukemia induction, which is 
caused by the c-MYC oncogene [81], a mechanism previously shown in T-ALL cells 
upon ZMIZ1.  
In conclusion, we found that the ZMIZ1 gene was up regulated in AML patients 
with poor prognosis, which might be due to its connection to c-MYC. Ideally an 
inhibitor of ZMIZ1 would be interesting to examine for its capacity to decrease 
proliferation of leukemic blast cells but as such not is available and alternative 
approach would be to use inhibitors towards the transcription factor c-MYC which 
recently has been described [169]. The decreased expression of the tumour suppressor 
gene PRDX2 linked to poor prognosis in AML might be used as a predictor of clinical 
outcome in AML. 
Dealing with chemotherapy resistance in AML patients is a big challenge. A 
majority of the AML patients will have a recurrent disease within the first two years 
after diagnosis and the treatment response after relapse is poor. How to circumvent 
resistance to therapy is clinically relevant and has attracted a lot of interest. Despite 
that, there is still a great need of knowledge. For chemotherapy resistance in AML as 
well as in other tumour types a number of signalling aberrations are evident such as 
decreased drug-uptake, activation of DNA-repair mechanisms and evading drug-
induced cell death e.g. apoptosis [73] [170] [74].  
In paper IV we took a global approach and assessed if 380 previously MDR-related 
genes [120] had a different expression in AML samples from the time of diagnosis and 
at relapse. Performing unsupervised hierarchical clustering on paired samples from 11 
individual AML patients, we found that five pairs were clustering apart and thus 
demonstrated a change in gene expression at time of relapse as compared to diagnosis. 
The genes that differ in expression may provide insight into what contributes to the 
development of chemotherapy resistance in AML and why AML at relapse are more 
resistant to treatment. It has earlier been shown that MDR1 (i.e. ABCB1) usually are 
present in a low level in AML at time of diagnosis [74], which corresponds well with a 
good response of induction treatment. Moreover, MDR1 is also demonstrated to have 
an increased level at relapse [142], supporting a poorer response to therapy at relapse. 
The expression level of MDR1 seems to increase with age [42] and in some studies it 
has been found to be predictive for poor outcome [171] [172] [74]. MDR1 is also 
reported to have an increased level in secondary leukemias [142]. One can think that 
genes contributing to relapse may change their mutation status thereby altering their 
function and in this contribute to a chemotherapy refractory phenotype.   
There was an enormous heterogeneity in gene expression in accordance to FAB 
classification, but for samples taken at diagnosis, two genes showed a positive 
correlation and four genes a negative correlation to maturation status in AML cells. 
Genes expressed in diagnostic samples and which showed a correlation to CR duration 
would be of interest since those genes may be one of the reasons for relapse or a 
predictor of recurrent disease. Our study did not reveal any significant relations that 
fulfilled FDR <15%. This may be due to a small amount of samples. It is also possible 
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that there are genetic aberrations that in fact is appearing after induction treatment and 
leading to a new cytogenetic signature compared to the one found at diagnosis.   
In support of the above, is the study by Walter et al, who reported that the 
development of secondary leukemia is dynamic and processed by multiple cycles of 
mutations and clonal selection [159]. They suggest that not only the presence of 
recurrent mutation, but also by the clone from which they arise may contribute to 
progression [159].  
To study differences in disease progression at diagnosis and in relapse we made a 
patient-by-patient analysis to determine whether the individual patients gene expression 
pattern differed between the two time points. Remarkable, in each patient samples at 
the time of relapse, there was an enormous heterogeneity, where the expressed genes 
likely represent different mechanisms of resistance, which all may contribute to the 
recurrent disease. Interestingly, in five of the patients (in patient-by-patient analysis) we 
found an increased expression of MDR1 at relapse, as described above this gene is well 
described to contribute to relapse in AML, but the diverse expression of MDR genes 
among the patients makes it likely that there are different genes contributing to relapse 
in different patients or different subgroups of disease. The diverse outcome in 
molecular analyses when comparing diagnostic and relapse samples suggests that 
systemic chemotherapies and/or leukemic blast cell selection have a considerable 
influence on the clonal evolution. This means that personalized therapy is an important 
way to go to achieve continued improvement in therapy response, but also tricky. With 
a large amount of genetic data in each individual patient suggesting a possible effect on 
resistance or residual disease, one problem is to know which target or targets, is the 
most clinically relevant. A lot of clinical challenges still remain unsolved.  
In summary, comparing AML patient cohorts with short vs. long CR duration our 
data demonstrate major differences in the RNA-expression of genes known to be 
involved in important regulatory events in normal and leukemic haematopoiesis. The 
differences are detectable already at diagnosis and may therefore be valuable in 
predicting AML outcome and for identification of new therapeutic biomarkers (paper 
III). In training cohort we found RUNX1T1 to be markedly up-regulated in patients 
with short CR duration, indicating that RUNX1T1 may signal poor long-term 
prognosis. Additional data from an unrelated validation cohort highlighted further 
differential genes of possible clinical significance, TCF3, CXCL3 and ZMIZ1 which 
were found to be up-regulated in patients with poorer prognosis and PRDX2 which was 
down-regulated in the same group (paper III). 
By analysing 380 genes associated with MDR and correlated these to 11 paired 
AML patient samples, we revealed that 6 out of 11 patients clustered together 
indicating that leukemic blast cells at relapse had the same origin as in the first sample 
(paper IV). The other 5 clustered apart, where the leukemic clone cannot be traced back 
to the same origin, but are perceived to be a newly developed clone. Patient-by-patient 
analysis showed that 10 of 11 patients at relapse expressed an increased amount of 
ABC transporters that have been shown to mediate multidrug resistance (paper IV). 
Those findings underline the importance of individual molecular diagnostics for 
specific individual treatment. 
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6. SUMMARY AND CONCLUSION 
Paper 1 
Our results from GO-treated AML cell lines and primary AML cells pinpoint the 
importance, not only of CD33-expression but also of p38 MAPK activation with 
subsequent initiation of mitochondrial depolarization and caspase-3 activation, as 
molecular determinants for clinical GO responsiveness in GO-sensitive cells. None of 
the above events occurred in GO-resistant AML cells upon GO-treatment. We could 
also, for the first time, show that activation of Bak/Bax appeared to be required for GO-
induced apoptosis and that resistance to GO may be located upstream of Bak/Bax.  
Paper II 
We demonstrated that, caspase-2 was cleaved in GO-responsive AML cells but not 
in GO resistant cells after in vitro treatment. Thus caspase-2 likely has a critical role in 
the intracellular cell death signalling after GO treatment in AML cells. Caspase-2 
probably acts in an alternative route to caspase-3 activation that acts in parallel to the 
intrinsic pathway. Blocking caspase-2 did not alter pro-apoptotic activation of Bak, Bax 
or cleavage of Bid. For molecular markers, such as caspase-2 and caspase-3, it is 
desirable with further analyses of both full length and activated proteins to correlate 
with response to GO treatment. This is to find out whether there is an increased 
cleavage in responders and a higher expression after GO treatment. Cell lines are 
suitable for initial studies, but to make it clear that the results are useful in clinical 
situation, analysis of primary patient cells are needed.  
Paper III 
Gene expression analyses are powerful in finding important prognostic and/or 
predictive markers in AML.  We compared AML patients with short CR duration (i.e. 
poor prognosis) to those with a long CR duration (i.e. better prognosis) and found a 
large difference in gene expression in the two groups. Our most striking finding was a 
remarkable up-regulation of the RUNX1T1 gene in patients with poor outcome. 
Pathway analyses linked RUNX1T1 to TCF3, which is reported to have tumour-
initiating capacity in solid tumours and are involved in cell signalling leading to 
increased proliferation. By silencing TCF3 we might be able to decrease proliferation 
in AML cells. In silico comparison revealed ZMIZ1 to be up-regulated in patients with 
poor clinical outcome. This is a gene involved in tumourgenesis, probably due to 
indirect activation of c-MYC and this makes ZMIZ1 a possible target for personalized 
therapy by using a ZMIZ1 inhibitor.  PRDX2, a tumour suppressor gene, was found to 
be down-regulated in AML patients with poor prognosis, thus a potential predictor of 
clinical outcome in AML. 
Paper IV 
We investigated the clinical relevance of 380 genes, known to affect the response to 
chemotherapy, in 11 paired samples (i.e. from diagnosis and at relapse) from adult 
AML patients. Hierarchical clustering revealed six patients clustering together, 
suggesting recurrence from the same leukemic origin, while 5 paired samples clustered 
apart. In patient-by-patient analyses of paired samples, we observed that all patients had 
a unique gene signature representing different resistance mechanisms. Those results 
pinpoint the importance of genetic and molecular diagnostics for personalized therapy. 
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